The Study
OR31-08 The FcRn Inhibitor Batoclimab Rapidly Normalizes Thyroid Function and Improves Clinical Outcomes in Graves’ Disease
This study watched 25 people take a new medicine and saw their symptoms get better. But it didn’t compare them to anyone who didn’t take the medicine, so we don’t know if the medicine actually caused the improvement — maybe they got better on their own.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
This study tested a new medicine called batoclimab that removes harmful antibodies causing the thyroid to overproduce hormones in people with Graves’ disease.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 520 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — patients felt less anxious, had slower heart rates, needed fewer beta blockers, and had visibly less bulging eyes, meaning real improvements in daily life.
- 2After one week, thyroid hormone levels dropped sharply; by week 12, 19 out of 25 people had normal hormone levels, 14 stopped all thyroid meds, and eye swelling improved by about 2 mm.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Journal of the Endocrine Society
Year
2025
Authors
MDPhD George Jean Kahaly, PharmD Jan Wolf, Anna-Lena Ganz, MSc Maximillian Luffy, PhD Katherine Albert, MD Farah Ali, PhD E Lin, MD PhD William Macias
Related Content
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.